SILLAJEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,810 KRW | -0.31% |
|
+2.67% | -20.23% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 5.01B 3.67M 5.05M | Sales 2023 | 3.94B 2.88M 3.97M | Capitalization | 620B 454M 624M |
|---|---|---|---|---|---|
| Net income 2022 | -24.59B -18M -24.77M | Net income 2023 | -20.37B -14.91M -20.51M | EV / Sales 2022 | 131 x |
| Net cash position 2022 | 59.87B 43.83M 60.29M | Net cash position 2023 | 39.6B 28.99M 39.88M | EV / Sales 2023 | 147 x |
| P/E ratio 2022 |
-29.1
x | P/E ratio 2023 |
-30.5
x | Employees | 42 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.11% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.31% | ||
| 1 week | +2.67% | ||
| Current month | +2.67% | ||
| 1 month | +0.84% | ||
| 3 months | -12.23% | ||
| 6 months | +4.23% | ||
| Current year | -20.23% |
1 week
4 655.00
5 000.00
1 month
4 325.005 140.00
Current year
4 325.006 620.00
1 year
3 950.007 260.00
3 years
3 950.0016 550.00
5 years
3 950.0061 500.00
10 years
3 950.00152 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Kyung-Mi Yang
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Ji-Won Choi
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Yong-Jae Jang
BRD | Director/Board Member | 57 | - |
Myung-Seok Song
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 4,810 | -0.31% | 685,518 |
| 24-05-03 | 4,825 | +0.73% | 409,566 |
| 24-05-02 | 4,790 | +2.24% | 1,069,225 |
| 24-04-30 | 4,685 | +0.32% | 402,231 |
End-of-day quote Korea S.E., May 06, 2024
More quotes
SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.23% | 366M | |
| +10.44% | 106B | |
| +0.82% | 104B | |
| +6.72% | 23.25B | |
| -13.89% | 22.5B | |
| -6.64% | 18.7B | |
| -37.26% | 17.95B | |
| -10.98% | 16.99B | |
| +8.67% | 14.26B | |
| +41.08% | 12.76B |
- Stock Market
- Equities
- A215600 Stock